Ovarian Cancer Clinical Trials in Minneapolis

Showing 61-80 of 179 trials

MT2021-27 FT538 Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

NCT05708924

To determine the maximum tolerated dose (MTD) of FT538 monotherapy when administered via intraperitoneal (IP) catheter and in combination with intravenous (IV) enoblituzumab in patients with recurrent ovarian, fallopian tube, and primary peritoneal cancer.

CancerSolid TumorOvarian Cancer+2 more

Masonic Cancer Center, University of Minnesota1 participantsStarted Apr 2023

Minneapolis, Minnesota, United States

Active Not RecruitingPhase 3< 1 mile

Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery

NCT04498117

Study to compare the safety and efficacy of oregovomab versus placebo, administered in combination with specific cycles of a standard six-cycle chemotherapy regimen (paclitaxel and carboplatin), for the treatment of subjects with newly diagnosed advanced ovarian cancer who have undergone optimal debulking.

Carcinoma, Ovarian EpithelialOvarian NeoplasmsOvarian Cancer+7 more

CanariaBio Inc.615 participantsStarted Aug 2020

Phoenix, Arizona, United States • Tucson, Arizona, United States • Concord, California, United States +145 more locations

MT2021-27 FT538 Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery

Ovarian Cancer Trials in Other Cities

Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy

Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors

A Study to Investigate LYL797 in Adults With Solid Tumors

Oral AMXT 1501 Dicaprate in Combination With IV DFMO

A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian Cancer

FPA150 in Patients With Advanced Solid Tumors

p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246

89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors

A Study of KB-0742 in Participants With Relapsed or Refractory Solid Tumors Including Platinum Resistant High Grade Serous Ovarian Cancer (HGSOC)

A Study of ZN-c3 in Patients With Ovarian Cancer

Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC

Study of the Safety, Pharmacokinetics and Efficacy of Tinostamustine in Patients With Advanced Solid Tumors.

A Study of LY2880070 in Participants With Advanced or Metastatic Cancer

A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies

Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules

Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors

A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors

Other Conditions in Minneapolis